BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

In a report released yesterday, Mark Lipacis from Evercore ISI maintained a Hold rating on Qualcomm (QCOM – Research Report), with a price ...

Wall Street drifted to a mixed close as drops for Ford Motor and Qualcomm worked against buoyant fashion and cigarette stocks ...

The Dow Jones Industrial Average ( ^DJI) fell 0.3%. The S&P 500 ( ^GSPC) rose more than 0.3%, and the tech-heavy Nasdaq Composite ( ^IXIC) popped 0.5% on the heels of two winning days in a row for the ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Wall Street is drifting Thursday as gains for fashion brands and cigarette makers help offset drops for Ford Motor and ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Wall Street experiences mixed performance as fashion and tobacco stocks surge, while automotive and tech sectors face ...

Stay updated on the latest stock market trends and company earnings. Discover the impact of market gains and profit reports ...

U.S. stock futures are edging mostly higher as market participants focus on tech stocks and corporate earnings; Honeywell announces a split of its automation, aerospace, and advan ...